CHARIOT: Our first dose escalation trial using the time to event continual reassessment method – design, difficulties, delivery
CHARIOT is a single-arm open-label, phase I dose escalation trial and is the first trial examining the combination of radiotherapy, chemotherapy, and the ataxia telangiectasia mutated Rad3-related (ATR) inhibitor M6620 in patients with oesophageal cancer. The aim is to identify the maximum tolerated...
| Main Authors: | , , , |
|---|---|
| Format: | Conference item |
| Published: |
University of Cambridge
2018
|